Companies/US/XERS

XERIS BIOPHARMA HOLDINGS, INC.

Income flow

Annual
XERS 10-K Income StatementPeriod 2025-12-31Source 10-K
Recorlev$139MGvoke$94MKeveyis$48MRoyalty Contract And Other Revenue$9MProduct Other$2MRevenue$292M+44% Y/YGross profit$249M+50% Y/YCost of revenue$43MOperating profit$25MOperating expenses$224MNet profit$554,000Tax$24MSG&A$182MR&D & other$42M

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · USD
By activity
By activity$292M
  • Recorlev$139M47.7%
  • Gvoke$94M32.3%
  • Keveyis$48M16.3%
  • Royalty Contract And Other Revenue$9M3.0%
  • Product Other$2M0.7%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.00%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.0.0%Shares outTotal shares currently outstanding (issued and not retired).182.3MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).176.0M